Sonoma Biotherapeutics
Jennifer Abrams has a diverse background in biology and pharmaceutical research. With experience in companies like Sonoma Biotherapeutics, Precision For Medicine, and Merck, Jennifer has held roles such as Senior Manager, Director, and Senior Scientist. Jennifer's academic background includes a PhD in Microbiology and Molecular Genetics from The University of Texas Health Science Center at Houston. Jennifer has also been involved in various research roles at institutions such as UCSF, University of Houston-Downtown, and Texas A&M University. Throughout their career, Jennifer has focused on drug discovery research, biochemical and cellular assays, and investigating disease mechanisms.
Sonoma Biotherapeutics
1 followers
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.